Beam Therapeutics Q2 net loss $122.7M; first patient dosed in BEAM-302 pivotal trial

Beam Therapeutics Inc.

Net loss of $122.7M ($1.18 per share) vs $102.1M loss in Q2 2025; R&D expenses $95.1M.
First patient dosed in global pivotal cohort of BEAM-302 for AATD; updated data at ERS Congress Sept 2026.
Dosing complete for all patients in BEACON trial of risto-cel for SCD; BLA submission expected as early as year-end 2026.
FDA cleared IND for BEAM-304 in PKU; clinical start-up activities underway.
Cash $1.2B as of June 30, 2026; with $200M from Sixth Street, runway into mid-2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.